Lipum AB

Novel target for treatment of inflammatory diseases

Lipum aims for better quality of life for the millions suffering from chronic inflammatory diseases. We have discovered that bile salt-stimulated lipase (BSSL) plays an important role in these diseases and are developing a therapeutic antibody that can inhibit its action. In November 2018 Lipum was granted 2.2 million euros from Horizon 2020, the EU framework program for research and development, and clinical trials will start during year 2021.

Dr Einar Pontén, CEO
An exciting development based on a novel target molecule and convincing pre-clinical data.

Fakta om Lipum AB

Lipum AB
Tvistevägen 48C
907 36 Umeå
Se på karta

Västerbottens län
Umeå kommun

Telefon: +46 90 340 34 30

VAT nummer: SE556813599901

Anställda: 3

Se hemsidan

Contact Persons

Einar Pontén
Direkt telefon: +46 903403430

Sänd till en kollega